BRIEF-Boehringer Ingelheim Start Of Phase II Clinical Trial Evaluating Its Investigational Triple GLP-1/GIP/NPY2 Receptor Agonist, BI 3034701

July 16 (Reuters) - BOEHRINGER INGELHEIM:

* BOEHRINGER INGELHEIM: START OF PHASE II CLINICAL TRIAL EVALUATING ITS INVESTIGATIONAL TRIPLE GLP-1/GIP/NPY2 RECEPTOR AGONIST, BI 3034701 Source text: Further company coverage: India's ambitious space programme has entered an unusual phase, not because of a rocket launch or a planetary mission, but because of the people behind them.

After more than 100 scientists reportedly resigned from the Indian Space Research Organisation (ISRO) while working on critical national missions, the Department of Space (DoS) has stepped in with stricter resignation norms aimed at preventing disruption to strategic projects, including the country's first human spaceflight mission, Gaganyaan.

The move has sparked a wider debate: Is India witnessing a worrying talent exodus from its premier space agency, or is the

India's ambitious space programme has entered an unusual phase, not because of a rocket launch or a planetary mission, but because of the people behind them.

After more than 100 scientists reportedly resigned from the Indian Space Research Organisation (ISRO) while working on critical national missions, the Department of Space (DoS) has stepped in with stricter resignation norms aimed at preventing disruption to strategic projects, including the country's first human spaceflight mission, Gaganyaan.

The move has sparked a wider debate: Is India witnessing a worrying talent exodus from its premier space agency, or is the